Summary
The pharmacokinetics of verapamil in five healthy volunteers were investigated on 4 occasions during chronic administration of deuterated verapamil. There was no statistically significant difference in oral clearance, terminal half-life, bioavailability, morning trough level and peak concentration or in the time of their occurrence on the four occasions. The plasma clearance, however, exhibited considerable inter- and intra-individual variation, ranging between 26.3% and 85.4% and 12.0% and 48.0%, respectively. Comparison of these pharmacokinetic parameters with data from previous single dose studies in the same subjects revealed a significant (p<0.05) decrease in the clearance and an increase in the apparent bioavailability of verapamil during chronic administration, although no difference in the half-life was found. Due to the considerable variation in the oral clearance of verapamil during chronic dosing, steady-state conditions in a strict pharmacokinetic sense may never be attained, and pharmacokinetic data obtained in single dose studies will be of limited value in predicting steady-state plasma concentrations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alexanderson B (1972) Pharmacokinetics of nortriptyline in man after single and multiple oral doses: the predictability of steady-state plasma concentrations from single dose plasma-level data. Eur J Clin Pharmacol 4: 82–91
Alvan G (1978) Individual differences in the disposition of drugs metabolised in the body. Clin Pharmacokinet 3: 155–175
Alvares AP, Kappas A, Eiseman JL, Anderson KE, Pantuck CB, Pantuck EJ, Hsiao K-C, Garland WA, Conney AH (1979) Intraindividual variation in drug disposition. Clin Pharmacol Ther 26: 407–419
Daneshmend TK, Jackson L, Roberts CJC (1981) Physiological and pharmacological variability in estimated hepatic blood flow in man. Br J Clin Pharmacol 11: 491–496
Daniel WW (1978) Applied nonparametric statistics. Houghton Mifflin, Boston
Eichelbaum M, Ende M, Remberg G, Schomerus M, Dengler HJ (1979) The metabolism of DL-[14C] verapamil in man. Drug Metabol Dispos 7: 145–148
Eichelbaum M, Albrecht M, Kliems G, Schäfer K, Somogyi A (1980a) Influence of meso-caval shunt surgery on verapamil kinetics, bioavailability and response. Br J Clin Pharmacol 10: 527–529
Eichelbaum M, Birkel P, Grube E, Gütgemann U, Somogyi A (1980b) Effects of verapamil on P-R intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment. Klin Wochenschr 58: 919–925
Eichelbaum M, Somogyi A, von Unruh GE, Dengler HJ (1981a) Simultaneous determination of the intravenous and oral pharmacokinetic parameters of d,l-verapamil using stable isotope labelled verapamil. Eur J Clin Pharmacol 19: 133–137
Eichelbaum M, Dengler HJ, Somogyi A, von Unruh GE (1981b) Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets. Eur J Clin Pharmacol 19: 127–131
Freedman SB, Richmond DR, Ashley JJ, Kelly DT (1981) Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clin Pharmacol Ther 30: 644–652
Harapat SR, Kates RE (1980) High-performance liquid chromatographic analysis of verapamil. II. Simultaneous quantitation of verapamil and its active metabolite, norverapamil. J Chromatogr 181: 484–489
Harris PA, Riegelman S (1969) Influence of the route of administration on the area under the plasma concentration-time curve. J Pharm Sci 58: 71–75
Jack DB, Quarterman CP, Zaman R, Kendall MJ (1982) Variability of beta-blocker pharmacokinetics in young volunteers. Eur J Clin Pharmacol 23: 37–42
Jähnchen E, Bechtold H, Kasper W, Fersting F, Just H, Heykants J, Meinertz T (1979) Lorcainide 1. Saturable presystemic elimination. Clin Pharmacol Ther 26: 187–195
Kaltenbach M, Hopf R, Keller M (1976) Calciumantagonistische Therapie bei hypertrophobstruktiver Kardiomyopathie. Dtsch Med Wochenschr 101: 1284–1287
Krikler DM (1974) Verapamil in cardiology. Eur J Cardiol 2: 3–10
Kuwada M, Tateyama T, Tsutsumi J (1981) Simultaneous determination of verapamil and its seven metabolites by high performance liquid chromatography. J Chromatogr 222: 507–511
Melander A, Danielson K, Scherstén B, Wåhlin E (1977) Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther 22: 108–112
Rosing DR, Kent KM, Borer JS, Seides SF, Maron BJ, Epstein SE (1979) Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects Circulation 60: 1201–1207
Rowland M (1972) Influence of route of administration on drug availability. J Pharm Sci 61: 70–74
Rowland M, Tucker G (1982) Symbols in Pharmacokinetics. Br J Clin Pharmacol 14: 7–13
Schomerus M, Spiegelhalder B, Stieren B, Eichelbaum M (1976) Physiological disposition of verapamil in man. Cardiovasc Res 10: 605–612
Schwartz JB, Keefe DL, Kirsten E, Kates RE, Harrison DC (1982) Prolongation of verapamil elimination kinetics during chronic oral administration. Am Heart J 104: 198–202
Shand DG, Hammill SC, Aanonsen L, Pritchett ELC (1981) Reduced verapamil clearance during long-term oral administration. Clin Pharmacol Ther 30: 701–703
Shepherd AMM, Ludden TM, McNay JL, Lin M-S (1980) Hydralazine kinetics after single and repeated oral doses. Clin Pharmacol Ther 28: 804–811
Singh BN, Ellrodt G, Peter CT (1978) Verapamil: a review of its pharmacological properties and therapeutic use. Drugs 15: 169–197
Somogyi A, Albrecht M, Kliems G, Schäfer K, Eichelbaum M (1981) Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol 12: 51–60
Somogyi A, Eichelbaum M, Gugler R (1982) Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data. Eur J Clin Pharmacol 22: 85–90
Spiegelhalder B, Eichelbaum M (1977) Determination of verapamil in human plasma by mass fragmentography using stable-labelled verapamil as internal standard. Arzneimittelforsch 27: 94–97
Vestal RE (1978) Drug use in the elderly: a review of problems and special considerations. Drugs 16: 358–382
Wilkinson GR (1975) Pharmacokinetics of drug disposition: hemodynamic considerations. Ann Rev Pharmacol Toxicol 15: 11–27
Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390
Williams RL, Benet LZ (1980) Drug pharmacokinetics in cardiac and hepatic disease. Ann Rev Pharmacol Toxicol 20: 389–413
Wood AJJ, Carr K, Vestal RE, Belcher S, Wilkinson GR, Shand DG (1978) Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol 6: 345–350
Woodcock BG, Schulz W, Kober G, Rietbrock N (1981) Direct determination of hepatic extraction of verapamil in cardiac patients. Clin Pharmacol Ther 30: 52–56
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eichelbaum, M., Somogyi, A. Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Eur J Clin Pharmacol 26, 47–53 (1984). https://doi.org/10.1007/BF00546708
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00546708